tirzepatide

Q: What is tirzepatide?

Tirzepatide is a dual GLP-1 and GIP receptor agonist, FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (obesity). It represents the first dual-incretin drug, combining two complementary metabolic pathways in a single molecule.

Q: What does tirzepatide do?

Tirzepatide reduces appetite, enhances insulin response, and improves glucose control via dual GLP-1 and GIP receptor activation. The SURMOUNT-1 obesity trial showed mean weight loss of approximately 22.5% of body weight over 72 weeks at the highest dose, the largest effect seen for any FDA-approved weight-loss drug at the time.

Q: How is tirzepatide typically administered?

Tirzepatide is administered as a once-weekly subcutaneous injection. FDA-approved Zepbound dosing starts at 2.5mg per week and titrates over 16-20 weeks through 5mg, 7.5mg, 10mg, 12.5mg, and a maximum of 15mg per week depending on individual response and tolerability.

Q: What are the side effects of tirzepatide?

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and decreased appetite. The profile is similar to semaglutide but sometimes more intense at higher doses. Serious risks include pancreatitis, gallbladder problems, and a boxed warning for thyroid C-cell tumors based on rodent studies.

Q: Is tirzepatide FDA approved?

Yes. Tirzepatide was FDA-approved as Mounjaro in May 2022 for type 2 diabetes, and as Zepbound in November 2023 for chronic weight management.

Q: How much does tirzepatide cost?

Branded Mounjaro and Zepbound retail for approximately $1000-1300 per month without insurance. Compounding pharmacies have offered tirzepatide at $300-600 per month during FDA-designated shortage periods. On the research-chemical market it sells for a fraction of the branded-drug price.

mounjaro and zepbound. GLP-1 plus GIP dual agonist. beats semaglutide head-to-head on weight loss.

tier S · weight loss · 22.5% SURMOUNT-1 wt loss

verdict

the dual GLP-1/GIP agonist that beat semaglutide head-to-head. mounjaro for diabetes, zepbound for obesity, same molecule.

if you're asking whether to take tirzepatide over semaglutide — SURPASS-2 went to tirzepatide on A1C reduction. SURMOUNT-5 went to tirzepatide on weight loss, 20.2% vs 13.7% at 72 weeks. insurance coverage and side-effect tolerance decide most of the rest. Lilly's self-pay starts at $299/month for Zepbound vials.

if you're asking what happens when you stop — SURMOUNT-4 showed the weight comes back. this is a chronic metabolic drug by design, not a course. the metabolic adaptation is the point and the cost.

if you came in worried about long-term safety — GI side effects (nausea, constipation, diarrhea) are the dominant story and most users tolerate them. gastroparesis lawsuits are live since 2023. rare serious AEs (pancreatitis, gallbladder events) sit at trial-baseline rates. SURPASS-CVOT and SUMMIT extend the record into cardiovascular and HFpEF territory.

based on published evidence and disclosed clinical practice. not medical advice. dose and protocol conversations belong with a clinician.

why S-tier

objectively the most effective FDA-approved weight loss drug. beats sema head-to-head by 5+ percentage points. dual-receptor mechanism hits harder than single. manufacturing scaled by Lilly at levels no peptide has ever seen. safety profile similar to sema. S because the data is overwhelming, trials are massive, and real-world outcomes match the trial data.

the core tension

Beats semaglutide head-to-head. Dual-agonist (GLP-1 + GIP) hits harder than single. Built Eli Lilly into the first trillion-dollar pharma. The category is moving toward triple-agonists, but tirzepatide is the benchmark every new weight-loss drug gets measured against.

what it is

A 39-amino-acid synthetic peptide. Dual agonist, hits the GLP-1 and GIP receptors at once. Sold by Eli Lilly as Mounjaro (type 2 diabetes) and Zepbound (obesity).

what it does

Slows gastric emptying, blunts appetite, boosts insulin response to food. The dual GLP-1/GIP mechanism beats GLP-1-only drugs on weight loss. SURMOUNT-1: 22.5% mean loss at 15mg over 72 weeks, the largest sustained effect for an FDA-approved obesity drug at the time.

origin

Lilly chemists built tirzepatide in the late 2010s on top of earlier dual-agonist work. FDA approved Mounjaro for T2D in May 2022, Zepbound for obesity in November 2023. Within two years it was one of the most-prescribed weight-loss drugs in the US.

why researchers are interested

Beats semaglutide head-to-head in SURPASS-2. Same once-weekly injection. Side-effect profile is similar, mostly GI (nausea, constipation, diarrhea), and most users tolerate it. Elite efficacy plus Mounjaro/Zepbound brand pull made adoption inevitable.

does it work

Yes. Phase-3 evidence is unambiguous: ~22% body weight reduction sustained for 72 weeks. SURPASS-CVOT (NEJM 2025) met non-inferiority for MACE vs dulaglutide and favored tirzepatide on expanded MACE (HR 0.88). SUMMIT (NEJM 2024, n=731 HFpEF + obesity) showed HR 0.62 for cardiovascular death or worsening heart failure. The S-tier bar is drug-grade human evidence. Tirzepatide clears it easily. LillyDirect self-pay starts at $299 and rises by dose. Medicare GLP-1 Bridge begins July 1, 2026 for eligible beneficiaries at $50/month. BALANCE is a separate CMS model. The catch is the same as every GLP-1. Stop the drug, weight comes back.

claims vs the data

more effective than semaglutide — supported — SURMOUNT-5 head-to-head 2024: 20.2% tirz vs 13.7% sema at 72 weeks.
causes 20%+ weight loss — supported — SURMOUNT-1: 22.5% at 15mg dose. SURMOUNT-5 vs sema: 20.2%.
better tolerated than sema — weak — GI sides similar in magnitude. discontinuation rates comparable.
works for type 2 diabetes — supported — SURPASS trials: HbA1c reductions 2.0-2.4%, best-in-class glycemic control.
no muscle loss — contradicted — DEXA data: ~25-30% of total loss is lean mass without resistance training. similar to sema.
safe to use forever — unverified — <4 years of human data as of 2026. long-term safety of any GLP-1 unknown.
compounded versions are identical — partially true — some are. some aren't. FDA stopped the shortage designation late 2024, most compounding now prohibited.
tirzepatide is only a weight-loss drug — contradicted — The obesity effect is the headline, but the newer record is broader: FDA approved Zepbound for obstructive sleep apnea, SURMOUNT-OSA showed disease-level sleep-apnea outcomes, and SUMMIT put tirzepatide into the HFpEF plus obesity conversation. The drug is now a cardiometabolic platform, not just a scale-number drug.

key facts

molecular formula: C₂₂₅H₃₄₈N₄₈O₆₈
molecular weight: 4813.45 g/mol
amino acids: 39
half-life: ~5 days
type: GIP/GLP-1 dual agonist
CAS: 2023788-19-2
22.5% avg weight loss (surmount-1)
$36.5B 2025 global revenue
#1 best-selling drug on earth
71% share of new US obesity Rx

frequently asked questions

What is tirzepatide?

Tirzepatide is a dual GLP-1 and GIP receptor agonist, FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (obesity). It represents the first dual-incretin drug, combining two complementary metabolic pathways in a single molecule.

What does tirzepatide do?

Tirzepatide reduces appetite, enhances insulin response, and improves glucose control via dual GLP-1 and GIP receptor activation. The SURMOUNT-1 obesity trial showed mean weight loss of approximately 22.5% of body weight over 72 weeks at the highest dose, the largest effect seen for any FDA-approved weight-loss drug at the time.

How is tirzepatide typically administered?

Tirzepatide is administered as a once-weekly subcutaneous injection. FDA-approved Zepbound dosing starts at 2.5mg per week and titrates over 16-20 weeks through 5mg, 7.5mg, 10mg, 12.5mg, and a maximum of 15mg per week depending on individual response and tolerability.

What are the side effects of tirzepatide?

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and decreased appetite. The profile is similar to semaglutide but sometimes more intense at higher doses. Serious risks include pancreatitis, gallbladder problems, and a boxed warning for thyroid C-cell tumors based on rodent studies.

Is tirzepatide FDA approved?

Yes. Tirzepatide was FDA-approved as Mounjaro in May 2022 for type 2 diabetes, and as Zepbound in November 2023 for chronic weight management.

How much does tirzepatide cost?

Branded Mounjaro and Zepbound retail for approximately $1000-1300 per month without insurance. Compounding pharmacies have offered tirzepatide at $300-600 per month during FDA-designated shortage periods. On the research-chemical market it sells for a fraction of the branded-drug price.

related peptides

semaglutide — head-to-head SURMOUNT-5: 20.2% vs 13.7%
retatrutide — triple-agonist successor in development
liraglutide — first-gen GLP-1 in this class

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.